All In Biotech

Drug Trial Radar · NCT02258542

A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA

A Multicentre, Double-blind, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-acting β2 Agonist (BORA)

Last checked: Nov 20, 2026Latest source record: Aug 21, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,133 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,133

Actual

Start

Nov 19, 2014

Primary completion

Oct 18, 2017

Study completion Jul 2, 2018

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 7, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Other
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize the safety profile of benralizumab administration in asthma patients who have completed one of the three predecessor studies: D3250C00017, D3250C00018 or D3250C00020.

Conditions

  • Asthma

Interventions

  • BenralizumabBiological

    Benralizumab administered subcutaneously

  • BenralizumabBiological

    Benralizumab administered subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Basophils, Full Analysis Set, Excluding MELTEMI PatientsTime frame: Week 56
  2. Change From Baseline in Basophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)Time frame: Week 108
  3. Change From Baseline in Leukocytes, Full Analysis Set, Excluding MELTEMI PatientsTime frame: Week 56
  4. Change From Baseline in Leukocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)Time frame: Week 108
  5. Change From Baseline in Lymphocytes, Full Analysis Set, Excluding MELTEMI PatientsTime frame: Week 56
  6. Change From Baseline in Lymphocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)Time frame: Week 108
  7. Change From Baseline in Neutrophils, Full Analysis Set, Excluding MELTEMI PatientsTime frame: Week 56
  8. Change From Baseline in Neutrophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)Time frame: Week 108
  9. Change From Baseline in Eosinophils, Full Analysis Set, Excluding MELTEMI PatientsTime frame: Week 56
  10. Change From Baseline in Eosinophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)Time frame: Week 108
  11. Change From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set, Excluding MELTEMI PatientsTime frame: Week 56
  12. Change From Baseline in ALT, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)Time frame: Week 108
  13. Change From Baseline in Aspartate Aminotransferase (AST), Full Analysis Set, Excluding MELTEMI PatientsTime frame: Week 56
  14. Change From Baseline in AST, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)Time frame: Week 108
  15. Change From Baseline in Bilirubin, Full Analysis Set, Excluding MELTEMI PatientsTime frame: Week 56
  16. Change From Baseline in Bilirubin, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)Time frame: Week 108

Locations

429 sites in 24 countries. Site status is shown where the registry gives one.

  • Research Site

    Andalusia, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Scottsboro, Alabama

  • Research Site

    Glendale, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Alhambra, California

  • Research Site

    Bakersfield, California

  • Research Site

    Newport Beach, California

  • Research Site

    Redondo Beach, California

  • Research Site

    Roseville, California

  • Research Site

    Sacramento, California

  • Research Site

    San Jose, California

  • Research Site

    Stockton, California

  • Research Site

    Walnut Creek, California

  • Research Site

    Westminster, California

  • Research Site

    Woodland, California

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Denver, Colorado

  • Research Site

    Wheat Ridge, Colorado

  • Research Site

    New Haven, Connecticut

  • Research Site

    Brandon, Florida

  • Research Site

    Clearwater, Florida

  • Research Site

    Cutler Bay, Florida

  • Research Site

    Doral, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Homestead, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Ocala, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Winter Park, Florida

  • Research Site

    Albany, Georgia

  • Research Site

    Gainesville, Georgia

Showing 40 of 429 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.